+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Systemic Sclerosis-Associated Interstitial Lung Disease (SSC-ILD) - Epidemiology Forecast To 2028

  • ID: 4855542
  • Report
  • November 2019
  • Region: Global
  • 60 pages
  • DelveInsight
1 of 2
“Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) - Epidemiology Forecast to 2028” report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of SSc-ILD in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2017-2028

Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) - Epidemiology

The Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) epidemiology division provides the insights about historical and current patient pool and forecasted trend for all seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the total disease prevalence, diagnosed cases, treatable cases and gender specific prevalent population in the US, EU5 and Japan.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, total diagnosed cases and total treatable cases) scenario of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to this research, total prevalent population of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) in seven major markets was found to be 71,375 in 2017.

Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Report Insights
  • The report covers detailed overview of SSc-ILD explaining its causes, symptoms, pathophysiology, diagnosis and treatment patterns.
  • The report provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, and UK) and Japan.
  • The Report highlights the unmet needs of SSc-ILD.
  • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology by total prevalent population, diagnosed cases, treatable cases and gender specific prevalent population in 7MM.
Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Report Key Strengths
  • 10 Year Forecast
  • 7MM Coverage
  • Prevalent cases
  • Diagnosed cases
  • Treatable cases
  • Gender specific prevalent population
Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Report Assessment
  • Patient Segmentation
  • Disease Risk & Burden
  • Factors driving growth in a specific patient population
Note: Product cover images may vary from those shown
2 of 2
1. Key Insights

2. Systemic Sclerosis-associated Interstitial Lung Disease: Disease Background and Overview
2.1. Introduction
2.2. Causes
2.3. Risk Factors
2.4. Signs and Symptoms
2.5. Pathophysiology
2.6. Diagnostic Approach
2.6.1. Diagnostic algorithm for Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)
2.6.2. Management of Systemic Sclerosis-associated Interstitial Lung Disease
2.6.3. Biomarkers in Systemic Sclerosis-associated Interstitial Lung Disease

3. Organizations contributing toward SSc-ILD

4. KOL's Views: Systemic Sclerosis-associated Interstitial Lung Disease

5. Epidemiology and Patient Population
5.1. Key Findings

6. 7MM Total Prevalent Patient Population of Systemic Sclerosis-associated Interstitial Lung Disease

7. Country Wise-Epidemiology of SSc-ILD
7.1. United States
7.1.1. Assumptions and Rationale
7.1.2. Total Prevalent Population of SSc-ILD
7.1.3. Total Gender Specific Prevalent Population of SSc-ILD
7.1.4. Total Diagnosed Cases of SSc-ILD
7.1.5. Total Treatable Cases of SSc-ILD
7.2. Europe
7.2.1. Assumptions and Rationale
7.3. Germany
7.3.1. Total Prevalent Population of SSc-ILD
7.3.2. Total Gender Specific Prevalent Population of SSc-ILD
7.3.3. Total Diagnosed Cases of SSc-ILD
7.3.4. Total Treatable Cases of SSc-ILD
7.4. France
7.4.1. Total Prevalent Population of SSc-ILD
7.4.2. Total Gender Specific Prevalent Population of SSc-ILD
7.4.3. Total Diagnosed Cases of SSc-ILD
7.4.4. Total Treatable Cases of SSc-ILD
7.5. Italy
7.5.1. Total Prevalent Population of SSc-ILD
7.5.2. Total Gender Specific Prevalent Population of SSc-ILD
7.5.3. Total Diagnosed Cases of SSc-ILD
7.5.4. Total Treatable Cases of SSc-ILD
7.6. Spain
7.6.1. Total Prevalent Population of SSc-ILD
7.6.2. Total Gender Specific Prevalent Population of SSc-ILD
7.6.3. Total Diagnosed Cases of SSc-ILD
7.6.4. Total Treatable Cases of SSc-ILD
7.7. The United Kingdom
7.7.1. Total Prevalent Population of SSc-ILD
7.7.2. Total Gender Specific Prevalent Population of SSc-ILD
7.7.3. Total Diagnosed Cases of SSc-ILD
7.7.4. Total Treatable Cases of SSc-ILD
7.8. Japan
7.8.1. Assumptions and Rationale
7.8.2. Total Prevalent Population of SSc-ILD
7.8.3. Total Gender Specific Prevalent Population of SSc-ILD
7.8.4. Total Diagnosed Cases of SSc-ILD
7.8.5. Total Treatable Cases of SSc-ILD

8. Case Reports
8.1. Scleroderma-related interstitial lung disease: reporting four cases of SSc-ILD in the US
8.2. Systemic scleroderma-related interstitial pneumonia associated with borderline pulmonary arterial hypertension - Case report of a Japanese woman
8.3. Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease

9. Appendix

10. Capabilities

11. Disclaimer

12. About the Publisher

List of Tables
Table 1 Quantitative and semi-quantitative scoring for SSc-ILD through HRCT: Wells et al.
Table 2 High-resolution computed tomography advantages and drawbacks
Table 3 Main biomarkers associated with SSc-ILD
Table 4 Main biomarkers associated with SSc-ILD
Table 5 Organizations contributing toward SSc-ILD
Table 6 Total Prevalent Population of SSc-ILD in the 7MM (2017-2028)
Table 7 Total Prevalent Population of SSc-ILD in the US (2017-2028)
Table 8 Gender specific prevalent population of SSc-ILD in the US (2017-2028)
Table 9 Diagnosed cases of SSc-ILD in the US (2017-2028)
Table 10 Treatable cases of SSc-ILD in the US (2017-2028)
Table 11 Total Prevalent Population of SSc-ILD in Germany (2017-2028)
Table 12 Gender specific prevalent population of SSc-ILD in Germany (2017-2028)
Table 13 Diagnosed cases of SSc-ILD in Germany (2017-2028)
Table 14 Treatable cases of SSc-ILD in Germany (2017-2028)
Table 15 Total Prevalent Population of SSc-ILD in France (2017-2028)
Table 16 Gender specific prevalent population of SSc-ILD in France (2017-2028)
Table 17 Diagnosed cases of SSc-ILD in France (2017-2028)
Table 18 Treatable cases of SSc-ILD in France (2017-2028)
Table 19 Total Prevalent Population of SSc-ILD in Italy (2017-2028)
Table 20 Gender specific prevalent population of SSc-ILD in Italy (2017-2028)
Table 21 Diagnosed cases of SSc-ILD in Italy (2017-2028)
Table 22 Treatable cases of SSc-ILD in Italy (2017-2028)
Table 23 Total Prevalent Population of SSc-ILD in Spain (2017-2028)
Table 24 Gender specific prevalent population of SSc-ILD in Spain (2017-2028)
Table 25 Diagnosed cases of SSc-ILD in Spain (2017-2028)
Table 26 Treatable cases of SSc-ILD in Spain (2017-2028)
Table 27 Total Prevalent Population of SSc-ILD in the UK (2017-2028)
Table 28 Gender specific prevalent population of SSc-ILD in the UK (2017-2028)
Table 29 Diagnosed cases of SSc-ILD in the UK (2017-2028)
Table 30 Treatable cases of SSc-ILD in the UK (2017-2028)
Table 31 Total Prevalent Population of SSc-ILD in Japan (2017-2028)
Table 32 Gender specific prevalent population of SSc-ILD in Japan (2017-2028)
Table 33 Diagnosed cases of SSc-ILD in Japan (2017-2028)
Table 34 Treatable cases of SSc-ILD in Japan (2017-2028)

List of Figures
Figure 1 Total Prevalent Population of SSc-ILD in the 7 MM (2017)
Figure 2 Total Prevalent Population of SSc-ILD in the 7 MM (2028)
Figure 3 Causes of SSc-ILD
Figure 4 Histological sections of normal lung tissue and lung tissue with ILD
Figure 5 Risk Factors of SSc- ILD
Figure 6 Symptoms associated with SSc-ILD
Figure 7 Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)
Figure 8 Diagnostic algorithm for SSc-ILD
Figure 9 Management of SSc-ILD
Figure 10 Total Prevalent Patient Population of SSc-ILD in the 7MM (2017-2028)
Figure 11 Total Prevalent Population of SSc-ILD in the US (2017-2028)
Figure 12 Gender specific prevalent population of SSc-ILD in the US (2017-2028)
Figure 13 Diagnosed cases of SSc-ILD in the US (2017-2028)
Figure 14 Treatable cases of SSc-ILD in the US (2017-2028)
Figure 15 Total Prevalent Population of SSc-ILD in Germany (2017-2028)
Figure 16 Gender specific prevalent population of SSc-ILD in Germany (2017-2028)
Figure 17 Diagnosed cases of SSc-ILD in Germany (2017-2028)
Figure 18 Treatable cases of SSc-ILD in Germany (2017-2028)
Figure 19 Total Prevalent Population of SSc-ILD in France (2017-2028)
Figure 20 Gender specific prevalent population of SSc-ILD in France (2017-2028)
Figure 21 Diagnosed cases of SSc-ILD in France (2017-2028)
Figure 22 Treatable cases of SSc-ILD in France (2017-2028)
Figure 23 Total Prevalent Population of SSc-ILD in Italy (2017-2028)
Figure 24 Gender specific prevalent population of SSc-ILD in Italy (2017-2028)
Figure 25 Diagnosed cases of SSc-ILD in Italy (2017-2028)
Figure 26 Treatable cases of SSc-ILD in Italy (2017-2028)
Figure 27 Total Prevalent Population of SSc-ILD in Spain (2017-2028)
Figure 28 Gender specific prevalent population of SSc-ILD in Spain (2017-2028)
Figure 29 Diagnosed cases of SSc-ILD in Spain (2017-2028)
Figure 30 Treatable cases of SSc-ILD in Spain (2017-2028)
Figure 31 Total Prevalent Population of SSc-ILD in the UK (2017-2028)
Figure 32 Gender specific prevalent population of SSc-ILD in the UK (2017-2028)
Figure 33 Diagnosed cases of SSc-ILD in the UK (2017-2028)
Figure 34 Treatable cases of SSc-ILD in the UK (2017-2028)
Figure 35 Total Prevalent Population of SSc-ILD in Japan (2017-2028)
Figure 36 Gender specific prevalent population of SSc-ILD in Japan (2017-2028)
Figure 37 Diagnosed cases of SSc-ILD in Japan (2017-2028)
Figure 38 Treatable cases of SSc-ILD in Japan (2017-2028)
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll